Reading BRKR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BRKR free→
Bruker (BRKR)
NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Intact
$55.80-1.47%
Close 2026-06-16 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, but earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, while risk is elevated and the sector backdrop is a headwind. Peer multiples imply a price about 36% below where it trades (it looks expensive on this basis); the read is fair, but weakening. If BRKR cuts guidance on the next call, that could have a meaningful negative impact. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Devices
- Market cap
- $8.26B
- Employees
- —
- IPO date
- 2000-04-14
- Next earnings
- 2026-08-03
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 7 valuation methods, at three horizons. Current price $55.80. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfull
$41.05consensus
Range $32.62 – $59.00
vs price: +36% above
Method agreement — · 7 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$120.59consensus
Range $95.42 – $144.83
vs price: -54% below
Method agreement — · 5 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Re-ratingmedium confidence
At $56 BRKR trades at 40× p/e — 1.7× the 23× p/e peer median, and above its own 29× history. The market is re-rating it beyond its own range; our $41 fair value is medium-confidence here. Analysts: $45–$53. Not investment advice.
Multiple (P/E)
39.9x
peer 23.2x · own history 29.3x
Premium
1.7x peer
1.4x its own history
Growth the price needs
36%
our forecast 2%
Our fair value
$41.05
range $32.62 – $59.00
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fullfair — but weakening12-month view
What's priced inUnjustified
The market is pricing in roughly 36% near-term growth, well above our forecast of about 2%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
79th pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted -12.42x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
neutral6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bearish12 analysts, 64% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.00 → $0.38. 0 raised, 11 cut, 12 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 1 maintained. 64% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: neutral
- Capital allocation
- neutral
- Earnings discipline
- neutral
- Margin discipline
- strong
- Balance sheet
- neutral
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-16
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$195.
How much price usually moves either way.
On a bad day, this stock has moved -$485.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,985.
Deepest peak-to-trough drop in the last year.
elevatedas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · valuation_labelsmall change
Valuation label changed from 'expensive' to 'full'.
The valuation changed, moving from "expensive" to "full." Risk fell. The sector backdrop remains a headwind. Recent financial performance is strong, but earnings quality is described as loss-making.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceQuartersactive 4d
Watch for Q2 organic revenue growth returning to positive
Why it matters: If the company grows again, it will help meet FY26 revenue goals. This shows recovery.
What confirms / what disproves
Confirms:Q2 organic revenue growth reported above 0% year over year.
Disproves:Q2 organic revenue growth remains negative year over year.
Management priorities
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-06-0610d agoYahoo! Finance
Signals growth aligns with revenue guidance.
Strongly reinforcesConfirmed
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ABT, SYK, and MDT keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting BRKR and other Healthcare names. Worth watching these names for early signals.
- If BRKR raises forward guidance on the next earnings call (currently REAFFIRMED as of 2026-05-06), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If BRKR beats again next quarter like it did this past one (a big beat of +35% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
Downside triggers
- If BRKR cuts guidance on the next call (currently REAFFIRMED as of 2026-05-06), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like ABT, SYK, and MDT start missing or guiding lower, the Healthcare tailwind helping BRKR and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-061mo agoItem 2.02
Results of Operations and Financial Condition. On May 6, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…
Earnings preannouncementpositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+4.1 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.